Technicals

Coca-Cola European Partners’ (CCE) Q4 Earnings Top Estimates

Coca-Cola European Partners plc CCE , or CCEP, is the world’s largest independent Coca-Cola bottler based on revenue and serves over 300 million consumers across Western Europe, including Andorra, Belgium, continental France, Germany, Great Britain, Luxembourg, Monaco, the Netherlands, Norway, Portugal, Spain and Sweden. Investors should also note that earnings estimates have moved upward for CCE in the last 60 days. Last quarter, earnings met analysts' expectation […]

Technicals

Why Vulcan Materials (VMC) Might Surprise This Earnings Season

Investors are always looking for stocks that are poised to beat at earnings season and Vulcan Materials Company VMC may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Vulcan Materials is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat […]

Technicals

Waste Management (WM) Tops Q4 Earnings and Revenues Estimate

Houston-based Waste Management, Inc. WM is the largest provider of comprehensive waste management services in North America. With services to nearly 21 million residential, commercial, industrial and municipal customers, the company is well executing its initiative to refocus on the core business activities and instil price and cost discipline to achieve better margins and returns in the long run […]

Technicals

Nektar (NKTR) Surges: Stock Moves 11% Higher

Nektar Therapeutics NKTR was a big mover last session, as the company saw its shares rise more than 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $69.40 –$88.74 in the past one-month time frame, witnessed a sharp increase yesterday […]

Technicals

Incyte (INCY) Beats on Sales in Q4

Wilmington, DE-based Incyte Corporation INCY is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. Incyte’s lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved for the treatment of patients with polycythemia vera (PV), patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. Incyte continues to gain traction by Jakafi’s performance […]

Stock Analysts

Home Entertainment, Gaming to Drive Sony: Time to Invest?

One high-growth tech stock that is still flying under the radar and should be in investors’ spotlight is Sony Corporation SNE — the Japanese gaming giant. Sony’s shares have appreciated 55.2% over the past year, as the company enjoys solid momentum in games, music, and home entertainment — which also happens to be its highest-margin segments. This compares well with the industry ’s gain of 45.2%. […]

Stock Analysts

Hyatt Hotels (H) Tops Q4 Earnings & Revenues, Margins Fall

Hyatt Hotels Corporation H posted better-than-expected results for the fourth quarter of 2017, wherein both earnings and revenues surpassed the Zacks Consensus Estimate. Adjusted earnings of 23 cents per share beat the consensus estimate of 19 cents by 21.1%. Earnings, however, fell 20.7% year over year, reflecting a pressure in the quarter’s EBITDA margin […]

Stock Analysts

Agilent (A) Q1 Earnings & Revenues Beat, ’18 View Positive

Agilent Technologies, Inc A delivered first-quarter fiscal 2018 non-GAAP earnings of 66 cents per share, which beat the Zacks Consensus Estimate by 8 cents. The figure also increased 24.5% from the year-ago quarter. Revenues of $1.21 billion increased 13.2% year over year driven by strong growth across all regions, particularly Europe and Asia-Pacific […]